Trial Profile
A single region, retrospective analysis to study the safety and efficacy of Alemtuzumab in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2015 New trial record